Methadone as a “Tumor Theralgesic” against Cancer

Begre, 2002, Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers., J. Clin. Psychopharmacol., 22, 211, 10.1097/00004714-200204000-00017

Chevlen, 2003, Opioids: a review., Curr. Pain Headache Rep., 7, 15, 10.1007/s11916-003-0005-5

Chugh, 2008, A community-based evaluation of sudden death associated with therapeutic levels of methadone., Am. J. Med., 121, 66, 10.1016/j.amjmed.2007.10.009

Connolly, 2017, Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: association with clinical disease recurrence or metastasis., PLOS ONE, 12, 10.1371/journal.pone.0177105

Coppes, 2017, Indications for opioid antagonists., Curr. Pain Headache Rep., 21, 10.1007/s11916-017-0630-z

Cruciani, 2005, Measurement of QTc in patients receiving chronic methadone therapy., J. Pain Symptom Manage., 29, 385, 10.1016/j.jpainsymman.2004.06.012

de Stoutz, 1995, Opioid rotation for toxicity reduction in terminal cancer patients., J. Pain Symptom Manage., 10, 378, 10.1016/0885-3924(95)90924-C

Dean, 2004, Opioids in renal failure and dialysis patients., J. Pain Symptom Manage., 28, 497, 10.1016/j.jpainsymman.2004.02.021

Eap, 2002, Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence., Clin. Pharmacokinet., 41, 1153, 10.2165/00003088-200241140-00003

Elde, 1995, Distribution of neuropeptide receptors. New views of peptidergic neurotransmission made possible by antibodies to opioid receptors., Ann. N. Y. Acad. Sci., 757, 390, 10.1111/j.1749-6632.1995.tb17497.x

Fainsinger, 1993, Methadone in the management of cancer pain: a review., Pain, 52, 137, 10.1016/0304-3959(93)90125-9

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012., Int. J. Cancer, 136, E359, 10.1002/ijc.29210

Ferrari, 2004, Methadone–metabolism, pharmacokinetics and interactions., Pharmacol. Res., 50, 551, 10.1016/j.phrs.2004.05.002

Fishman, 2002, Methadone reincarnated: novel clinical applications with related concerns., Pain Med., 3, 339, 10.1046/j.1526-4637.2002.02047.x

Friesen, 2014, Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma., Cell Cycle, 13, 1560, 10.4161/cc.28493

Friesen, 2013, Cell death sensitization of leukemia cells by opioid receptor activation., Oncotarget, 4, 677, 10.18632/oncotarget.952

Heusch, 1999, Effects of bombesin on methadone-induced apoptosis of human lung cancer cells., Cancer Lett., 136, 177, 10.1016/S0304-3835(98)00335-8

Hewitt, 2000, The use of NMDA-receptor antagonists in the treatment of chronic pain., Clin. J. Pain, 16, S73, 10.1097/00002508-200006001-00013

Inturrisi, 1972, The levels of methadone in the plasma in methadone maintenance., Clin. Pharmacol. Ther., 13, 633, 10.1002/cpt1972135part1633

Kornick, 2003, QTc interval prolongation associated with intravenous methadone., Pain, 105, 499, 10.1016/S0304-3959(03)00205-7

Krantz, 2002, Torsade de pointes associated with very-high-dose methadone., Ann. Intern. Med., 137, 501, 10.7326/0003-4819-137-6-200209170-00010

Kreek, 1980, Methadone use in patients with chronic renal disease., Drug Alcohol Depend., 5, 197, 10.1016/0376-8716(80)90180-5

Kristensen, 1995, The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine., Life Sci., 56, L45, 10.1016/0024-3205(94)00426-S

Lamotte, 1976, Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section., Brain Res., 112, 407, 10.1016/0006-8993(76)90296-1

Lin, 2009, The effects of chiral isolates of methadone on the cardiac potassium channel IKr., Cardiology, 113, 59, 10.1159/000167043

Maneckjee, 1992, Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells., Proc. Natl. Acad. Sci. U.S.A., 89, 1169, 10.1073/pnas.89.4.1169

McGraw, 2012, Cytochrome P450 variations in different ethnic populations., Expert Opin. Drug Metab. Toxicol., 8, 371, 10.1517/17425255.2012.657626

McLean, 2015, Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence., J. Pain Symptom Manage., 50, 248, 10.1016/j.jpainsymman.2015.02.029

Mercadante, 2006, Opioid switching: a systematic and critical review., Cancer Treat. Rev., 32, 304, 10.1016/j.ctrv.2006.03.001

Mercadante, 2001, Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study., J. Clin. Oncol., 19, 2898, 10.1200/JCO.2001.19.11.2898

Mercadante, 2005, Rapid switching between transdermal fentanyl and methadone in cancer patients., J. Clin. Oncol., 23, 5229, 10.1200/JCO.2005.13.128

Meresaar, 1981, Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method., Eur. J. Clin. Pharmacol., 20, 473, 10.1007/BF00542102

Nersesyan, 2007, Current aproach to cancer pain management: availability and implications of different treatment options., Ther. Clin. Risk Manag., 3, 381

Nicholson, 2017, Methadone for cancer pain., Cochrane Database Syst. Rev., 2, 10.1002/14651858.CD003971.pub4

Nilsson, 1983, Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures., Eur. J. Clin. Pharmacol., 25, 497, 10.1007/BF00542117

Nilsson, 1982, Effect of urinary pH on the disposition of methadone in man., Eur. J. Clin. Pharmacol., 22, 337, 10.1007/BF00548403

Oda, 2001, Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation., J. Pharmacol. Exp. Ther., 298, 1021

Onken, 2017, Safety and tolerance of D,L-methadone in combination with chemotherapy in patients with glioma., Anticancer Res., 37, 1227, 10.21873/anticanres.11438

Paine, 2006, The human intestinal cytochrome P450 “pie”., Drug Metab. Dispos., 34, 880, 10.1124/dmd.105.008672

Pathan, 2012, Basic opioid pharmacology: an update., Br. J. Pain, 6, 11, 10.1177/2049463712438493

Peirano, 2016, Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit., Support Care Cancer, 24, 3551, 10.1007/s00520-016-3191-5

Porta-Sales, 2016, Efficacy and safety of methadone as a second-line opioid for cancer pain in an outpatient clinic: a prospective open-label study., Oncologist, 21, 981, 10.1634/theoncologist.2015-0503

Sawe, 1986, High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment., Clin. Pharmacokinet., 11, 87, 10.2165/00003088-198611020-00001

Singh, 2011, Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition., Leuk. Res., 35, 1649, 10.1016/j.leukres.2011.06.035

Singleton, 2014, Increased mu-opioid receptor expression in metastatic lung cancer., Br. J. Anaesth., i103, 10.1093/bja/aeu165

Takase, 2015, Methadone for patients with malignant psoas syndrome: case series of three patients., J. Palliat. Med., 18, 645, 10.1089/jpm.2014.0387

Tanigawara, 2000, Role of P-glycoprotein in drug disposition., Ther. Drug Monit., 22, 137, 10.1097/00007691-200002000-00029

van den Beuken-van Everdingen, 2016, Update on prevalence of pain in patients with cancer: systematic review and meta-analysis., J. Pain Symptom Manage., 51, e9.1070, 10.1016/j.jpainsymman.2015.12.340

Weschules, 2008, A systematic review of opioid conversion ratios used with methadone for the treatment of pain., Pain Med., 9, 595, 10.1111/j.1526-4637.2008.00461.x

Weschules, 2008, Actual and potential drug interactions associated with methadone., Pain Med., 9, 315, 10.1111/j.1526-4637.2006.00289.x

Wu, 1993, Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone., Br. J. Clin. Pharmacol., 35, 30, 10.1111/j.1365-2125.1993.tb05666.x

Yao, 2015, MOR1 expression in gastric cancer: a biomarker associated with poor outcome., Clin. Transl. Sci., 8, 137, 10.1111/cts.12246

Zhang, 2013, kappa-opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma., Hum. Pathol., 44, 1756, 10.1016/j.humpath.2012.11.025

Zimmermann, 2005, Rotation to methadone after opioid dose escalation: how should individualization of dosing occur?, J. Pain Palliat. Care Pharmacother., 19, 25, 10.1080/J354v19n02_05

Zylla, 2013, Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer., Cancer, 119, 4103, 10.1002/cncr.28345